NCT06744816 Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
| NCT ID | NCT06744816 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Peripheral Neuropathy Due to Chemotherapy |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-12-11 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2025-12-11 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.
Eligibility Criteria
Inclusion Criteria: * Participants diagnosed with pain of the lower extremity from chronic (\>90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at MD Anderson Cancer Center * Participants reporting baseline pain ≥ 4 (0-10 scale, NRS) * Participants age 18+ * Participants who have completed chemotherapy within the last year at the time of enrollment. Exclusion Criteria: * Participants with cognitive dysfunction * Participants with recent history (\<6 months) of drug or alcohol abuse * Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection * Participants with allergies to capsaicin or adhesives * Pregnant participants
Contact & Investigator
Saba Javed, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06744816 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Peripheral Neuropathy Due to Chemotherapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06744816 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06744816 currently recruiting?
Yes, NCT06744816 is actively recruiting participants. Contact the research team at sjaved@mdanderson.org for enrollment information.
Where is the NCT06744816 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06744816 clinical trial?
NCT06744816 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Saba Javed, MD at M.D. Anderson Cancer Center. The trial plans to enroll 20 participants.